ES2018 Blood Collection from Exact Sciences / ICON

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors. Click here to learn more.

IDR-OM-02

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study Of SGX942 (Dusquetide) For The Treatment Of Oral Mucositis In Patients Being Treated With Concomitant Chemoradiation For The Treatment Of Squamous Cell Carcinoma Of The Head And Neck. Click here to learn more.

Libretto / LOXO-292 EAP: Loxo Oncology, Inc.

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation. Click here to learn more.

MATCH (EAY131)

Molecular Analysis for Therapy Choice (MATCH). Click here to learn more.

MYPATHWAY (ML28897)

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents. Click here to learn more.

PICI0009

An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PDL-1, and CTLA-4) used as Monotherapy or in Combination in Patients with Cancer. Ask your doctor.

SPI-POZ-202

Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation. Click here to learn more.


Learn more about Solid Tumors >

Our Affiliations

 

 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started